At the annual general meeting on March 31, 2026, the approval of the 14th-term financial statements passed with 100% approval of the voting shares exercised. The standalone summary in the AGM result filing lists revenue of 4,423, an operating loss of 1,158 and net income of 324.
The unit appears to be KRW millions, which is consistent with the KRW 4.42 billion revenue figure compiled by Saramin. Net income is shown as positive despite the operating loss, and the cause could not be confirmed.
The same filing shows total assets of 3,189, total liabilities of 15,665, total equity of negative 12,475 and capital stock of 1,507. According to TheVC, the current ratio fell from 21.7% in 2023 to 16.1% in 2024 and recovered slightly to 16.8% in 2025.
On the business side, the company announced on June 2, 2026 that its Indonesian joint venture had signed a disease-prediction genetic testing supply contract with local medical institutions.
On October 3 and 4, 2026, it signed a multi-omics healthcare agreement with Longevity Medical System in Hanoi and Ho Chi Minh City. The filing list also shows a litigation-related filing on February 4, 2026 and an investor relations briefing result on May 11, 2026.
The counterparty and the claim amount of the lawsuit could not be confirmed. On the share price, the stock closed at KRW 1,863 on March 31, 2026, up 15.00% from the prior day. Per Investing.com, the price was KRW 2,100 on October 1, 2026, and the 52-week range is KRW 1,300 to KRW 4,015.
The October 27, 2026 price of KRW 1,350 (+3.85% day over day) sits near the 52-week low, and neither filings nor press reports explain the move over this stretch.